血浆致动脉硬化指数的临床研究进展  

Research progress of atherogenic index of plasma in atherosclerosis related diseases

作　　者：王雪华 李红建[1] WANG Xuehua;LI Hongjian(Hypertension Department,the Fifth Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830011,China)

机构地区：[1]新疆医科大学第五附属医院高血压科,新疆乌鲁木齐市830011

出　　处：《中国动脉硬化杂志》2022年第5期449-453,共5页Chinese Journal of Arteriosclerosis

基　　金：国家重点研发计划项目(2018YFC1311503)。

摘　　要：动脉粥样硬化作为大血管疾病原发病变的关键因素,研究证实血脂异常在动脉粥样硬化进程中有着非常重要的作用。目前大量国内外的研究表明,血浆致动脉硬化指数(AIP)与心血管疾病、动脉粥样硬化等慢性疾病密切相关,AIP作为一种新型综合性血脂指标,对早期心血管风险、代谢综合征、慢性肾脏病及免疫相关疾病等常见临床疾病均具有预测价值。本综述旨在总结AIP在临床方面的研究进展及其应用价值。Atherosclerosis(As)is a key factor in the primary lesions of macrovascular diseases,and dyslipidemia plays a very important role in the process of As.At present,a large number of studies at home and abroad have shown that atherogenic index of plasma(AIP)is closely related to cardiovascular disease,atherosclerosis and other chronic diseases.It is considered that AIP,as a new comprehensive blood lipid index,has predictive value for early cardiovascular risk,metabolic syndrome,chronic kidney disease,immune-related diseases and other common clinical diseases.The purpose of this review is to summarize the clinical research progress of AIP.

关 键 词：血浆致动脉硬化指数 血脂异常 心血管疾病 代谢综合征 慢性肾脏病 自身免疫性疾病 

分 类 号：R5[医药卫生—内科学]